Key result
Late SARS-CoV-2 myocarditis linked to acute biventricular heart failure in a transplant recipient with LVEF recovering to 46%.
Case Report (n=1)
No
This case highlights the potential for late post-myocarditis biventricular heart failure following SARS-CoV-2 infection in heart transplant recipients, which can partially recover with standard heart failure therapy and ICD implantation.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to possible late post-SARS-CoV-2 myocarditis in transplant recipients; hypothesis-generating and should not yet change practice.
This report describes the first heart transplantation recipient with acute biventricular heart failure symptoms caused by a post-myocarditis state, late after a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. No other viral pathogens could be detected. Computed tomography angiography did not show cardiac allograft vasculopathy, and myocardial biopsy demonstrated no clinically relevant rejection. Subsequent cardiovascular magnetic resonance imaging revealed extensive epicardial delayed enhancement without myocardial edema. Heart failure medication was initiated and an implantable cardioverter defibrillator was implanted (due to non-sustained ventricular tachycardias), leading to a partial recovery of the ejection fraction. Further studies are needed to investigate the number of heart transplant recipients with myocardial damage after a SARS-CoV-2 infection.
No takes yet. Share an insight, caveat, or question.
Roest et al. (2021) conducted a case report in COVID-19-related myocarditis post-heart transplantation (n=1). Heart failure medication and implantable cardioverter defibrillator was evaluated on Left ventricular ejection fraction (LVEF) recovery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: